China’s CDE grants breakthrough status approval to Abbisko’s HCC therapy
The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.
The China NMPA's CDE has granted breakthrough therapy designation approval to Abbisko Therapeutics’ irpagratinib for HCC.
What's Your Reaction?
